FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Toru Maruyama

Research Profile

Chemicals & Drugs

Phenomena

Living Beings

Rats
Mouse

Procedures

Fluorescence Spectrometry

Concepts & Ideas

Disorders

Anatomy

Livers

Co-author Network

Publications

TOP 3
Ryota Tanaka; Hiroshi Watanabe; Tohru Mizushima; Masaki Otagiri; Ken-Ichiro Tanaka; Victor Tuan Giam Chuang; Keisuke Hamasaki; Yu Ishima; Azusa Kodama; Toru Maruyama
Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression.
Yu Ishima; Toshiya Kai; Ulrich Kragh-Hansen; Yuki Ohya; Masaki Otagiri; Takuya Shinagawa; Shinji Yoneshige; Yukihiro Inomata; Toru Maruyama
UW solution improved with high anti-apoptotic activity by S-nitrosated human serum albumin.
Ai Minomo; Hiroshi Morioka; Toru Narisoko; Victor T G Chuang; Yu Ishima; Ulrich Kragh-Hansen; Toru Maruyama; Yoshiaki Suwa; Masaki Otagiri
Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Toru Maruyama (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Ryota Tanaka; Hiroshi Watanabe; Tohru Mizushima; Masaki Otagiri; Ken-Ichiro Tanaka; Victor Tuan Giam Chuang; Keisuke Hamasaki; Yu Ishima; Azusa Kodama; Toru Maruyama
Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced pulmonary fibrosis progression.
The Journal of pharmacology and experimental therapeutics 2013;345(2):271-83.
2013: Yu Ishima; Toshiya Kai; Ulrich Kragh-Hansen; Yuki Ohya; Masaki Otagiri; Takuya Shinagawa; Shinji Yoneshige; Yukihiro Inomata; Toru Maruyama
UW solution improved with high anti-apoptotic activity by S-nitrosated human serum albumin.
Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society 2013;30():36-42.
2013: Ai Minomo; Hiroshi Morioka; Toru Narisoko; Victor T G Chuang; Yu Ishima; Ulrich Kragh-Hansen; Toru Maruyama; Yoshiaki Suwa; Masaki Otagiri
Albumin domain II mutant with high bilirubin binding affinity has a great potential as serum bilirubin excretion enhancer for hyperbilirubinemia treatment.
Biochimica et biophysica acta 2013;1830(4):2917-23.
2013: Hiroshi Watanabe; Qiong Wu; Yohei Miyamoto; Makoto Nakajima; Tsuyoshi Noguchi; Masaki Otagiri; Hisae Tanaka; Motoko Tanaka; Masayuki Endo; Masafumi Fukagawa; Daisuke Honda; Yu Ishima; Daisuke Kadowaki; Keiichiro Kataoka; Shokei Kim-Mitsuyama; Shunsuke Kotani; Toru Maruyama
p-Cresyl sulfate causes renal tubular cell damage by inducing oxidative stress by activation of NADPH oxidase.
Kidney international 2013;83(4):582-92.
2013: yuki kondo; Toru Maruyama; Yohei Miyamoto; Keizo Sato; Yusuke Fukumoto; Naotaka Hamasaki; Sumio Hirata; Mitsuru Irikura; Yoichi Ishitsuka; Daisuke Kadowaki; Tetsumi Irie
Phosphoenolpyruvate, a glycolytic intermediate, as a cytoprotectant and antioxidant in ex-vivo cold-preserved mouse liver: a potential application for organ preservation.
The Journal of pharmacy and pharmacology 2013;65(3):390-401.
2013: Azusa Kodama; Victor T G Chuang; Masayuki Endo; Masafumi Fukagawa; Keisuke Hamasaki; Yu Ishima; Yohei Miyamoto; Masaki Otagiri; Hisae Tanaka; Ryota Tanaka; Hiroshi Watanabe; Qiong Wu; Toru Maruyama
A human serum albumin-thioredoxin fusion protein prevents experimental contrast-induced nephropathy.
Kidney international 2013;83(3):446-54.
2013: Shigeru Ogaki; Masaki Otagiri; Kazuaki Taguchi; Hiroshi Watanabe; Toru Maruyama
Carbon monoxide-bound red blood cells protect red blood cell transfusion-induced hepatic cytochrome P450 impairment in hemorrhagic-shock rats.
Drug metabolism and disposition: the biological fate of chemicals 2013;41(1):141-8.
2013: Kaori Watanabe; Takaaki Akaike; Yu Ishima; Toshiya Kai; Teruo Kuroda; Wakano Ogawa; Masaki Otagiri; Tomohiro Sawa; Ayaka Suenaga; Hiroshi Watanabe; Toru Maruyama
S-nitrosated α-1-acid glycoprotein kills drug-resistant bacteria and aids survival in sepsis.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2013;27(1):391-8.
2012: Daisuke Kadowaki; Kenichiro Kitamura; Toru Maruyama; Yuki Narita; Masaki Otagiri; Satomi Sumikawa; Kazuaki Taguchi; Kanami Arimizu; Victor Tuan Giam Chuang; Tetsumi Irie; Yoichi Ishitsuka; Sumio Hirata
Effect of acetaminophen on the progression of renal damage in adenine induced renal failure model rats.
Life sciences 2012;91(25-26):1304-8.
2012: Yu Ishima; Toshiya Kai; Ulrich Kragh-Hansen; Marie Hara; Aki Inoue; Masaki Otagiri; Ayaka Suenaga; Hiroshi Watanabe; Toru Maruyama
Elucidation of the therapeutic enhancer mechanism of poly-S-nitrosated human serum albumin against multidrug-resistant tumor in animal models.
Journal of controlled release : official journal of the Controlled Release Society 2012;164(1):1-7.
2012: Yohei Miyamoto; Masaki Otagiri; Keizo Sato; Hiroshi Watanabe; Victor Tuan Giam Chuang; Yu Ishima; Yasunori Iwao; Daisuke Kadowaki; Katsumi Mera; Toru Maruyama
A uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropionate induces cell damage to proximal tubular cells via the generation of a radical intermediate.
Biochemical pharmacology 2012;84(9):1207-14.
2012: Kazuaki Taguchi; Victor Tuan Giam Chuang; Toru Maruyama; Masaki Otagiri
Pharmaceutical aspects of the recombinant human serum albumin dimer: structural characteristics, biological properties, and medical applications.
Journal of pharmaceutical sciences 2012;101(9):3033-46.
2012: Yu Ishima; Toshiya Kai; Ulrich Kragh-Hansen; Toru Maruyama; Tomohiro Sawa; Takuya Shinagawa; Hiroshi Watanabe; Kaori Watanabe; Takaaki Akaike; Hitomi Hoshino; Masaki Otagiri
S-guanylation of human serum albumin is a unique posttranslational modification and results in a novel class of antibacterial agents.
Journal of pharmaceutical sciences 2012;101(9):3222-9.
2012: Hiroshi Watanabe; Yu Ishima; Daisuke Kadowaki; Shunsuke Kotani; Yohei Miyamoto; Shigeyuki Miyamura; Makoto Nakajima; Tsuyoshi Noguchi; Masaki Otagiri; Toru Maruyama
Interaction between two sulfate-conjugated uremic toxins, p-cresyl sulfate and indoxyl sulfate, during binding with human serum albumin.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(7):1423-8.
2012: K Kaneko; Toru Maruyama; V T G Chuang; T Ito; A Suenaga; Hiroshi Watanabe; Masaki Otagiri
Arginine 485 of human serum albumin interacts with the benzophenone moiety of ketoprofen in the binding pocket of subdomain III A and III B.
Die Pharmazie 2012;67(5):414-8.
2012: Yasunori Iwao; Ulrich Kragh-Hansen; Toru Maruyama; Katsumi Mera; Taishi Noguchi; Daisuke Honda; Yu Ishima; Ayaka Suenaga; Junji Yamada; Masaki Otagiri
Quantitative evaluation of the role of cysteine and methionine residues in the antioxidant activity of human serum albumin using recombinant mutants.
IUBMB life 2012;64(5):450-4.
2012: Hisakazu Komori; Toru Maruyama; Koji Nishi; Tsuyoshi Shuto; Ayaka Suenaga; Nao Uehara; Hiroshi Watanabe; Masaki Otagiri
Characterization of hepatic cellular uptake of α1-acid glycoprotein (AGP), part 2: involvement of hemoglobin β-chain on plasma membranes in the uptake of human AGP by liver parenchymal cells.
Journal of pharmaceutical sciences 2012;101(4):1607-15.
2012: Koji Nishi; Ayaka Suenaga; Nao Uehara; Hiroshi Watanabe; Naoko Fukunaga; Mari Kikuchi; Hisakazu Komori; Toru Maruyama; Kazuaki Matsumoto; Shogo Misumi; Keisuke Nakajou; Masaki Otagiri
Characterization of the hepatic cellular uptake of α(1) -acid glycoprotein (AGP), part 1: a peptide moiety of human AGP is recognized by the hemoglobin β-chain on mouse liver parenchymal cells.
Journal of pharmaceutical sciences 2012;101(4):1599-606.
2012: Yu Ishima; Toshiya Kai; Ulrich Kragh-Hansen; Hiroshi Maeda; Toru Maruyama; Ai Minomo; Di Chen; Jun Fang; Masaki Otagiri
S-Nitrosated human serum albumin dimer is not only a novel anti-tumor drug but also a potentiator for anti-tumor drugs with augmented EPR effects.
Bioconjugate chemistry 2012;23(2):264-71.
2012: yuki kondo; Masataka Kuroda; Toru Maruyama; Minako Nagatome; Keizo Sato; Yuta Tanaka; Naotaka Hamasaki; Sumio Hirata; Mitsuru Irikura; Yoichi Ishitsuka; Daisuke Kadowaki; Tetsumi Irie
Phosphoenolpyruvic acid, an intermediary metabolite of glycolysis, as a potential cytoprotectant and anti-oxidant in HeLa cells.
Biological & pharmaceutical bulletin 2012;35(4):606-11.
2011: Ai Minomo; Hiroshi Morioka; Kazuaki Taguchi; Makiyo Uchida; Hiroshi Watanabe; Victor T G Chuang; Yu Ishima; Ulrich Kragh-Hansen; Toru Maruyama; Masaki Otagiri
Biological characteristics of two lysines on human serum albumin in the high-affinity binding of 4Z,15Z-bilirubin-IXα revealed by phage display.
The FEBS journal 2011;278(21):4100-11.
2011: Yu Ishima; Toshiya Kai; Naohisa Katayama; Ulrich Kragh-Hansen; Toru Maruyama; Keisuke Nakajou; Kaori Watanabe; Fumika Yoshida; Takaaki Akaike; Masaki Otagiri
Cellular uptake mechanisms and responses to NO transferred from mono- and poly-S-nitrosated human serum albumin.
Free radical research 2011;45(10):1196-206.
2011: Masato Furukawa; Yu Ishima; Toru Maruyama; Kazuaki Taguchi; Ryota Tanaka; Hiroshi Watanabe; Victor Tuan Giam Chuang; Masaki Otagiri
Human serum albumin-thioredoxin fusion protein with long blood retention property is effective in suppressing lung injury.
Journal of controlled release : official journal of the Controlled Release Society 2011;154(2):189-95.
2011: Hiroshi Watanabe; Yohei Miyamoto; Masaki Otagiri; Toru Maruyama
Update on the pharmacokinetics and redox properties of protein-bound uremic toxins.
Journal of pharmaceutical sciences 2011;100(9):3682-95.
2011: Makoto Anraku; Daisuke Kadowaki; Kenichiro Kitamura; Akihiko Kuniyasu; Toru Maruyama; Ayaka Suenaga; Koji Takeuchi; Kimio Tomita; Hiroshi Watanabe; Masaki Otagiri
Quantitative analysis of cysteine-34 on the anitioxidative properties of human serum albumin in hemodialysis patients.
Journal of pharmaceutical sciences 2011;100(9):3968-76.
2011: Tomoe Kugimiya; Toru Maruyama; Yohei Misumi; Konen Obayashi; Masaki Otagiri; Shiori Saito; Makoto Shono; Yu Su; Masayoshi Tasaki; Mitsuharu Ueda; Yoshinobu Hoshii; Hirofumi Jono; Daisuke Kadowaki; Yukio Ando
Loss of functional albumin triggers acceleration of transthyretin amyloid fibril formation in familial amyloidotic polyneuropathy.
Laboratory investigation; a journal of technical methods and pathology 2011;91(8):1219-28.
2011: Kazuaki Taguchi; Toru Maruyama; Masaki Otagiri
Pharmacokinetic properties of hemoglobin vesicles as a substitute for red blood cells.
Drug metabolism reviews 2011;43(3):362-73.
2011: Katsumi Mera; Ryoji Nagai; Kazuhiro Takeo; Miyoko Izumi; Toru Maruyama; Masaki Otagiri
An autoantibody against N(ε)-(carboxyethyl)lysine (CEL): possible involvement in the removal of CEL-modified proteins by macrophages.
Biochemical and biophysical research communications 2011;407(2):420-5.
2011: Kenichi Kaneko; Victor Tuan Giam Chuang; Ai Minomo; Keishi Yamasaki; Nadhipuram V Bhagavan; Toru Maruyama; Masaki Otagiri
Histidine146 of human serum albumin plays a prominent role at the interface of subdomains IA and IIA in allosteric ligand binding.
IUBMB life 2011;63(4):277-85.
2011: Yohei Miyamoto; Hiroshi Watanabe; Masaki Otagiri; Toru Maruyama
New insight into the redox properties of uremic solute indoxyl sulfate as a pro- and anti-oxidant.
Therapeutic apheresis and dialysis : official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the Japanese Society for Dialysis Therapy 2011;15(2):129-31.
2011: Kazuaki Taguchi; Shigeru Ogaki; Hiroshi Watanabe; Daisuke Kadowaki; Hiromi Sakai; Koichi Kobayashi; Hirohisa Horinouchi; Toru Maruyama; Masaki Otagiri
Fluid resuscitation with hemoglobin vesicles prevents Escherichia coli growth via complement activation in a hemorrhagic shock rat model.
The Journal of pharmacology and experimental therapeutics 2011;337(1):201-8.
2011: Kazuaki Taguchi; Yasunori Iwao; Hiroshi Watanabe; Daisuke Kadowaki; Hiromi Sakai; Koichi Kobayashi; Hirohisa Horinouchi; Toru Maruyama; Masaki Otagiri
Repeated injection of high doses of hemoglobin-encapsulated liposomes (hemoglobin vesicles) induces accelerated blood clearance in a hemorrhagic shock rat model.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(3):484-9.
2011: Kazuaki Taguchi; Mayumi Miyasato; Hiroshi Watanabe; Hiromi Sakai; Eishun Tsuchida; Hirohisa Horinouchi; Koichi Kobayashi; Toru Maruyama; Masaki Otagiri
Alteration in the pharmacokinetics of hemoglobin-vesicles in a rat model of chronic liver cirrhosis is associated with Kupffer cell phagocyte activity.
Journal of pharmaceutical sciences 2011;100(2):775-83.
2010: Kazuaki Taguchi; Yukino Urata; Makoto Anraku; Hiroshi Watanabe; Keiichi Kawai; Teruyuki Komatsu; Eishun Tsuchida; Toru Maruyama; Masaki Otagiri
Superior plasma retention of a cross-linked human serum albumin dimer in nephrotic rats as a new type of plasma expander.
Drug metabolism and disposition: the biological fate of chemicals 2010;38(12):2124-9.
2010: Kazuaki Taguchi; Mayumi Miyasato; Hayato Ujihira; Hiroshi Watanabe; Daisuke Kadowaki; Hiromi Sakai; Eishun Tsuchida; Hirohisa Horinouchi; Koichi Kobayashi; Toru Maruyama; Masaki Otagiri
Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment.
Toxicology and applied pharmacology 2010;248(3):234-41.
2010: Shotaro Ikuta; Victor Chuang; Yu Ishima; Keisuke Nakajou; Masato Furukawa; Hiroshi Watanabe; Toru Maruyama; Masaki Otagiri
Albumin fusion of thioredoxin--the production and evaluation of its biological activity for potential therapeutic applications.
Journal of controlled release : official journal of the Controlled Release Society 2010;147(1):17-23.
2010: Yu Ishima; Shuichi Hiroyama; Ulrich Kragh-Hansen; Toru Maruyama; Tomohiro Sawa; Takaaki Akaike; Toshiya Kai; Masaki Otagiri
One-step preparation of S-nitrosated human serum albumin with high biological activities.
Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society 2010;23(2):121-7.
2010: Yohei Miyamoto; Yasunori Iwao; Yuka Tasaki; Keizo Sato; Yu Ishima; Hiroshi Watanabe; Daisuke Kadowaki; Toru Maruyama; Masaki Otagiri
The uremic solute indoxyl sulfate acts as an antioxidant against superoxide anion radicals under normal-physiological conditions.
FEBS letters 2010;584(13):2816-20.
2010: Kenshiro Hirata; Toru Maruyama; Hiroshi Watanabe; Hitoshi Maeda; Keisuke Nakajou; Yasunori Iwao; Yu Ishima; Hidemasa Katsumi; Mitsuru Hashida; Masaki Otagiri
Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics.
Journal of controlled release : official journal of the Controlled Release Society 2010;145(1):9-16.
2010: Naohisa Katayama; Keisuke Nakajou; Yu Ishima; Shotaro Ikuta; Jun-ichi Yokoe; Fumika Yoshida; Ayaka Suenaga; Toru Maruyama; Toshiya Kai; Masaki Otagiri
Nitrosylated human serum albumin (SNO-HSA) induces apoptosis in tumor cells.
Nitric oxide : biology and chemistry / official journal of the Nitric Oxide Society 2010;22(4):259-65.
2010: Katsumi Mera; Kazuhiro Takeo; Miyoko Izumi; Toru Maruyama; Ryoji Nagai; Masaki Otagiri
Effect of reactive-aldehydes on the modification and dysfunction of human serum albumin.
Journal of pharmaceutical sciences 2010;99(3):1614-25.
2010: Koji Nishi; Naoko Fukunaga; Tomomi Ono; Teruo Akuta; Nagahiko Yumita; Hiroshi Watanabe; Daisuke Kadowaki; Ayaka Suenaga; Toru Maruyama; Masaki Otagiri
Construction of an expression system for human alpha(1)-acid glycoprotein in E. coli: The roles of oligosaccharide moieties in structural and functional properties.
Drug metabolism and pharmacokinetics 2010;25(2):200-7.
2010: Kazuaki Matsumoto; Koji Nishi; Mari Kikuchi; Hiroshi Watanabe; Keisuke Nakajou; Hisakazu Komori; Daisuke Kadowaki; Ayaka Suenaga; Toru Maruyama; Masaki Otagiri
Receptor-mediated uptake of human alpha1-acid glycoprotein into liver parenchymal cells in mice.
Drug metabolism and pharmacokinetics 2010;25(1):101-7.
2009: Daisuke Kadowaki; Makoto Anraku; Yuka Tasaki; Kazuaki Taguchi; Kazuki Shimoishi; Hakaru Seo; Sumio Hirata; Toru Maruyama; Masaki Otagiri
Evaluation for antioxidant and renoprotective activity of olmesartan using nephrectomy rats.
Biological & pharmaceutical bulletin 2009;32(12):2041-5.
2009: Kazuaki Taguchi; Yukino Urata; Makoto Anraku; Hiroshi Watanabe; Daisuke Kadowaki; Hiromi Sakai; Hirohisa Horinouchi; Koichi Kobayashi; Eishun Tsuchida; Toru Maruyama; Masaki Otagiri
Hemoglobin vesicles, polyethylene glycol (PEG)ylated liposomes developed as a red blood cell substitute, do not induce the accelerated blood clearance phenomenon in mice.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(11):2197-203.
2009: Koji Nishi; Megumi Ueno; Yuka Murakami; Naoko Fukunaga; Teruo Akuta; Daisuke Kadowaki; Hiroshi Watanabe; Ayaka Suenaga; Toru Maruyama; Masaki Otagiri
A site-directed mutagenesis study of drug-binding selectivity in genetic variants of human alpha(1)-acid glycoprotein.
Journal of pharmaceutical sciences 2009;98(11):4316-26.
2009: Kazuaki Taguchi; Yukino Urata; Makoto Anraku; Toru Maruyama; Hiroshi Watanabe; Hiromi Sakai; Hirohisa Horinouchi; Koichi Kobayashi; Eishun Tsuchida; Toshiya Kai; Masaki Otagiri
Pharmacokinetic study of enclosed hemoglobin and outer lipid component after the administration of hemoglobin vesicles as an artificial oxygen carrier.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(7):1456-63.
2009: Kazuaki Taguchi; Toru Maruyama; Yasunori Iwao; Hiromi Sakai; Koichi Kobayashi; Hirohisa Horinouchi; Eishun Tsuchida; Toshiya Kai; Masaki Otagiri
Pharmacokinetics of single and repeated injection of hemoglobin-vesicles in hemorrhagic shock rat model.
Journal of controlled release : official journal of the Controlled Release Society 2009;136(3):232-9.
2009: Yasunori Iwao; Mikako Hiraike; Ulrich Kragh-Hansen; Keiichi Kawai; Ayaka Suenaga; Toru Maruyama; Masaki Otagiri
Altered chain-length and glycosylation modify the pharmacokinetics of human serum albumin.
Biochimica et biophysica acta 2009;1794(4):634-41.
2009: Toru Maruyama; Daisuke Kadowaki
[To facilitate the compliance of phosphate binder for the control of hyperphosphatemia in chronic kidney disease patients].
Clinical calcium 2009;19(2):248-52.
2009: Yu Ishima; Ulrich Kragh-Hansen; Toru Maruyama; Masaki Otagiri
Albumin as a nitric oxide-traffic protein: characterization, biochemistry and possible future therapeutic applications.
Drug metabolism and pharmacokinetics 2009;24(4):308-17.
2008: Yu Ishima; Takaaki Akaike; Ulrich Kragh-Hansen; Shuichi Hiroyama; Tomohiro Sawa; Ayaka Suenaga; Toru Maruyama; Toshiya Kai; Masaki Otagiri
S-nitrosylated human serum albumin-mediated cytoprotective activity is enhanced by fatty acid binding.
The Journal of biological chemistry 2008;283(50):34966-75.
2008: Yasunori Iwao; Keisuke Nakajou; Ryoji Nagai; Kenichiro Kitamura; Makoto Anraku; Toru Maruyama; Masaki Otagiri
CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products.
American journal of physiology. Renal physiology 2008;295(6):F1871-80.
2008: Katsumi Mera; Mime Nagai; Jonathan W C Brock; Yukio Fujiwara; Toshinori Murata; Toru Maruyama; John W Baynes; Masaki Otagiri; Ryoji Nagai
Glutaraldehyde is an effective cross-linker for production of antibodies against advanced glycation end-products.
Journal of immunological methods 2008;334(1-2):82-90.
2008: Naohisa Katayama; Keisuke Nakajou; Hisakazu Komori; Kunitoshi Uchida; Jun-Ichi Yokoe; Norikiyo Yasui; Hisashi Yamamoto; Toshiya Kai; Makoto Sato; Takenobu Nakagawa; Motohiro Takeya; Toru Maruyama; Masaki Otagiri
Design and evaluation of S-nitrosylated human serum albumin as a novel anticancer drug.
The Journal of pharmacology and experimental therapeutics 2008;325(1):69-76.
2008: Ken-ichi Kaneko; Hikaru Fukuda; Victor Chuang; Keishi Yamasaki; Kohichi Kawahara; Hitoshi Nakayama; Ayaka Suenaga; Toru Maruyama; Masaki Otagiri
Subdomain IIIA of dog albumin contains a binding site similar to site II of human albumin.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(1):81-6.
2007: Yu Ishima; Takaaki Akaike; Ulrich Kragh-Hansen; Shuichi Hiroyama; Tomohiro Sawa; Toru Maruyama; Toshiya Kai; Masaki Otagiri
Effects of endogenous ligands on the biological role of human serum albumin in S-nitrosylation.
Biochemical and biophysical research communications 2007;364(4):790-5.
2007: Yasunori Iwao; Mikako Hiraike; Ulrich Kragh-Hansen; Katsumi Mera; Taishi Noguchi; Makoto Anraku; Keiichi Kawai; Toru Maruyama; Masaki Otagiri
Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin.
Biochimica et biophysica acta 2007;1774(12):1582-90.
2007: Takamitsu Kosa; Koji Nishi; Toru Maruyama; Norifumi Sakai; Naoko Yonemura; Hiroshi Watanabe; Ayaka Suenaga; Masaki Otagiri
Structural and ligand-binding properties of serum albumin species interacting with a biomembrane interface.
Journal of pharmaceutical sciences 2007;96(11):3117-24.
2007: Kazuki Shimoishi; Makoto Anraku; Kenichiro Kitamura; Yuka Tasaki; Kazuaki Taguchi; Mitsuru Hashimoto; Eiko Fukunaga; Toru Maruyama; Masaki Otagiri
An oral adsorbent, AST-120 protects against the progression of oxidative stress by reducing the accumulation of indoxyl sulfate in the systemic circulation in renal failure.
Pharmaceutical research 2007;24(7):1283-9.
2007: Daisuke Kadowaki; Makoto Anraku; Yuka Tasaki; Kenichiro Kitamura; Shiho Wakamatsu; Kimio Tomita; Janusz M Gebicki; Toru Maruyama; Masaki Otagiri
Effect of olmesartan on oxidative stress in hemodialysis patients.
Hypertension research : official journal of the Japanese Society of Hypertension 2007;30(5):395-402.
2006: Koji Nishi; Yoshio Komine; Naoko Fukunaga; Toru Maruyama; Ayaka Suenaga; Masaki Otagiri
Involvement of disulfide bonds and histidine 172 in a unique beta-sheet to alpha-helix transition of alpha 1-acid glycoprotein at the biomembrane interface.
Proteins 2006;63(3):611-20.
2006: Sadaharu Matsushita; Victor Chuang; Masanori Kanazawa; Sumio Tanase; Keiichi Kawai; Toru Maruyama; Ayaka Suenaga; Masaki Otagiri
Recombinant human serum albumin dimer has high blood circulation activity and low vascular permeability in comparison with native human serum albumin.
Pharmaceutical research 2006;23(5):882-91.
2006: Yasunori Iwao; Makoto Anraku; Keishi Yamasaki; Ulrich Kragh-Hansen; Keiichi Kawai; Toru Maruyama; Masaki Otagiri
Oxidation of Arg-410 promotes the elimination of human serum albumin.
Biochimica et biophysica acta 2006;1764(4):743-9.
2005: Katsumi Mera; Makoto Anraku; Kenichiro Kitamura; Keisuke Nakajou; Toru Maruyama; Kimio Tomita; Masaki Otagiri
Oxidation and carboxy methyl lysine-modification of albumin: possible involvement in the progression of oxidative stress in hemodialysis patients.
Hypertension research : official journal of the Japanese Society of Hypertension 2005;28(12):973-80.
2005: Katsumi Mera; Makoto Anraku; Kenichiro Kitamura; Keisuke Nakajou; Toru Maruyama; Masaki Otagiri
The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst.
Biochemical and biophysical research communications 2005;334(4):1322-8.
2005: Koji Nishi; Yoshio Komine; Norifumi Sakai; Toru Maruyama; Masaki Otagiri
Cooperative effect of hydrophobic and electrostatic forces on alcohol-induced alpha-helix formation of alpha1-acid glycoprotein.
FEBS letters 2005;579(17):3596-600.
2004: Keishi Yamasaki; Toru Maruyama; Akira Takadate; Ayaka Suenaga; Ulrich Kragh-Hansen; Masaki Otagiri
Characterization of site I of human serum albumin using spectroscopic analyses: locational relations between regions Ib and Ic of site I.
Journal of pharmaceutical sciences 2004;93(12):3004-12.
2004: Makoto Anraku; Yasufumi Tsurusaki; Hiroshi Watanabe; Toru Maruyama; Ulrich Kragh-Hansen; Masaki Otagiri
Stabilizing mechanisms in commercial albumin preparations: octanoate and N-acetyl-L-tryptophanate protect human serum albumin against heat and oxidative stress.
Biochimica et biophysica acta 2004;1702(1):9-17.
2004: Koji Nishi; Toru Maruyama; H Brian Halsall; Tetsuro Handa; Masaki Otagiri
Binding of alpha1-acid glycoprotein to membrane results in a unique structural change and ligand release.
Biochemistry 2004;43(32):10513-9.
2004: Makoto Anraku; Kenichiro Kitamura; Ayumi Shinohara; Masataka Adachi; Ayaka Suenga; Toru Maruyama; Kei Miyanaka; Taku Miyoshi; Naoki Shiraishi; Hiroshi Nonoguchi; Masaki Otagiri; Kimio Tomita; Ayaka Suenaga
Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients.
Kidney international 2004;66(2):841-8.
2003: Keisuke Nakajou; Hiroshi Watanabe; Ulrich Kragh-Hansen; Toru Maruyama; Masaki Otagiri
The effect of glycation on the structure, function and biological fate of human serum albumin as revealed by recombinant mutants.
Biochimica et biophysica acta 2003;1623(2-3):88-97.
2003: Makoto Anraku; Ulrich Kragh-Hansen; Keiichi Kawai; Toru Maruyama; Yasuomi Yamasaki; Yoshinobu Takakura; Masaki Otagiri
Validation of the chloramine-T induced oxidation of human serum albumin as a model for oxidative damage in vivo.
Pharmaceutical research 2003;20(4):684-92.
2002: Koji Nishi; Norifumi Sakai; Yoshio Komine; Toru Maruyama; H Brian Halsall; Masaki Otagiri
Structural and drug-binding properties of alpha(1)-acid glycoprotein in reverse micelles.
Biochimica et biophysica acta 2002;1601(2):185-91.
2002: Kazuaki Matsumoto; Katsuaki Sukimoto; Koji Nishi; Toru Maruyama; Ayaka Suenaga; Masaki Otagiri
Characterization of ligand binding sites on the alpha1-acid glycoprotein in humans, bovines and dogs.
Drug metabolism and pharmacokinetics 2002;17(4):300-6.
2001: Takafumi Komori; Hirofumi Kai; Kazuki Shimoishi; K Kabu; A Nonaka; Toru Maruyama; K Tamura; Masaki Otagiri
Up-regulation by clarithromycin of alpha(1)-acid glycoprotein expression in liver and primary cultured hepatocytes.
Biochemical pharmacology 2001;62(10):1391-7.
2001: Hiroshi Watanabe; Ulrich Kragh-Hansen; Sumio Tanase; Keisuke Nakajou; M Mitarai; Yasunori Iwao; Toru Maruyama; Masaki Otagiri
Conformational stability and warfarin-binding properties of human serum albumin studied by recombinant mutants.
The Biochemical journal 2001;357(Pt 1):269-74.
2001: Kazuki Shimoishi; Hirofumi Kai; K Kabu; Takafumi Komori; Toru Maruyama; Masaki Otagiri
FK506 (tacrolimus) increases rat alpha1-acid glycoprotein expression in liver and primary cultured hepatocytes.
European journal of pharmacology 2001;420(2-3):91-5.
2001: Makoto Anraku; Keishi Yamasaki; Toru Maruyama; Ulrich Kragh-Hansen; Masaki Otagiri
Effect of oxidative stress on the structure and function of human serum albumin.
Pharmaceutical research 2001;18(5):632-9.
2000: Hiroshi Watanabe; Sumio Tanase; Keisuke Nakajou; Toru Maruyama; Ulrich Kragh-Hansen; Masaki Otagiri
Role of arg-410 and tyr-411 in human serum albumin for ligand binding and esterase-like activity.
The Biochemical journal 2000;349 Pt 3():813-9.
2000: Yasuhiro Tsutsumi; Toru Maruyama; Akira Takadate; H Shimada; Masaki Otagiri
Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.
Nephron 2000;85(1):60-4.
2000: K Yamasaki; M H Rahman; Y Tsutsumi; Toru Maruyama; S Ahmed; Ulrich Kragh-Hansen; Masaki Otagiri
Circular dichroism simulation shows a site-II-to-site-I displacement of human serum albumin-bound diclofenac by ibuprofen.
AAPS PharmSciTech 2000;1(2):E12.
1999: Keishi Yamasaki; Toru Maruyama; K Yoshimoto; Y Tsutsumi; R Narazaki; A Fukuhara; Ulrich Kragh-Hansen; Masaki Otagiri
Interactive binding to the two principal ligand binding sites of human serum albumin: effect of the neutral-to-base transition.
Biochimica et biophysica acta 1999;1432(2):313-23.
1999: Yasuhiro Tsutsumi; Toru Maruyama; Akira Takadate; M Goto; H Matsunaga; Masaki Otagiri
Interaction between two dicarboxylate endogenous substances, bilirubin and an uremic toxin, 3-carboxy-4-methyl-5-propyl-2-furanpropanoic acid, on human serum albumin.
Pharmaceutical research 1999;16(6):916-23.
1999: T Sakai; Toru Maruyama; T Sako; S Ahmed; X Zuidema; S Fujiyama; Masaki Otagiri
Stereoselective serum protein binding of ketoprofen in liver diseases.
Enantiomer 1999;4(5):477-82.
1998: Takafumi Komori; A Nonaka; Toru Maruyama; Masaki Otagiri
Effect of clarithromycin on alpha1-acid glycoprotein levels in normal and diabetic rats.
Research communications in molecular pathology and pharmacology 1998;101(3):233-40.
1998: Takamitsu Kosa; Toru Maruyama; Norifumi Sakai; Naoko Yonemura; Shoji Yahara; Masaki Otagiri
Species differences of serum albumins: III. Analysis of structural characteristics and ligand binding properties during N-B transitions.
Pharmaceutical research 1998;15(4):592-8.
1998: R Narazaki; H Watanabe; Toru Maruyama; A Suenaga; Masaki Otagiri
An immunological method for the detection of captopril-protein conjugate.
Archives of toxicology 1998;72(4):203-6.
1998: Takamitsu Kosa; Toru Maruyama; Masaki Otagiri
Species differences of serum albumins: II. Chemical and thermal stability.
Pharmaceutical research 1998;15(3):449-54.
1997: N Takamura; Toru Maruyama; Masaki Otagiri
Effects of uremic toxins and fatty acids on serum protein binding of furosemide: possible mechanism of the binding defect in uremia.
Clinical chemistry 1997;43(12):2274-80.
1997: Takamitsu Kosa; Toru Maruyama; Masaki Otagiri
Species differences of serum albumins: I. Drug binding sites.
Pharmaceutical research 1997;14(11):1607-12.
1997: R Narazaki; Toru Maruyama; Masaki Otagiri
Probing the cysteine 34 residue in human serum albumin using fluorescence techniques.
Biochimica et biophysica acta 1997;1338(2):275-81.
1997: R Narazaki; Toru Maruyama; Masaki Otagiri
Effect of N-B transition on the microenvironment surrounding 34Cys in human serum albumin.
Biological & pharmaceutical bulletin 1997;20(4):452-4.
1997: N Takamura; Toru Maruyama; S Ahmed; Ayaka Suenaga; Masaki Otagiri
Interactions of aldosterone antagonist diuretics with human serum proteins.
Pharmaceutical research 1997;14(4):522-6.
1996: K Yamasaki; Toru Maruyama; U Kragh-Hansen; Masaki Otagiri
Characterization of site I on human serum albumin: concept about the structure of a drug binding site.
Biochimica et biophysica acta 1996;1295(2):147-57.
1994: K Yamasaki; T Miyoshi; Toru Maruyama; A Takadate; Masaki Otagiri
Characterization of region Ic in site I on human serum albumin. Microenvironmental analysis using fluorescence spectroscopy.
Biological & pharmaceutical bulletin 1994;17(12):1656-62.
1994: H Imamura; Toru Maruyama; H Okabe; H Shimada; Masaki Otagiri
A simple and rapid fluorometric determination method of alpha 1-acid glycoprotein in serum using quinaldine red.
Pharmaceutical research 1994;11(4):566-70.
1993: M H Rahman; Toru Maruyama; T Okada; T Imai; Masaki Otagiri
Study of interaction of carprofen and its enantiomers with human serum albumin--II. Stereoselective site-to-site displacement of carprofen by ibuprofen.
Biochemical pharmacology 1993;46(10):1733-40.
1993: M H Rahman; Toru Maruyama; T Okada; K Yamasaki; Masaki Otagiri
Study of interaction of carprofen and its enantiomers with human serum albumin--I. Mechanism of binding studied by dialysis and spectroscopic methods.
Biochemical pharmacology 1993;46(10):1721-31.
1993: H Imamura; Toru Maruyama; Masaki Otagiri
Evaluation of quinaldine red as a fluorescent probe for studies of drug-alpha 1-acid glycoprotein interaction.
Biological & pharmaceutical bulletin 1993;16(9):926-9.
1993: Toru Maruyama; C C Lin; K Yamasaki; T Miyoshi; T Imai; M Yamasaki; Masaki Otagiri
Binding of suprofen to human serum albumin. Role of the suprofen carboxyl group.
Biochemical pharmacology 1993;45(5):1017-26.
1992: T Miyoshi; R Yamamichi; Toru Maruyama; Masaki Otagiri
Reversal of signs of induced cotton effects of dicumarol-alpha 1-acid glycoprotein systems by phenothiazine neuroleptics through ternary complexation.
Pharmaceutical research 1992;9(7):845-9.
1992: T Miyoshi; R Yamamichi; Toru Maruyama; A Takadate; Masaki Otagiri
Further characterization of reversal of signs of induced cotton effects of dicumarol derivatives-alpha 1-acid glycoprotein systems by protriptyline.
Biochemical pharmacology 1992;43(10):2161-7.
1992: Toru Maruyama; M A Furuie; Satoshi Hibino; Masaki Otagiri
Comparative study of interaction mode of diazepines with human serum albumin and alpha 1-acid glycoprotein.
Journal of pharmaceutical sciences 1992;81(1):16-20.
1991: Masaki Otagiri; T Miyoshi; R Yamamichi; Toru Maruyama; J H Perrin
Effects of tricyclic drug on induced circular dichroism spectra of dicumarol bound to alpha 1-acid glycoprotein.
Biochemical pharmacology 1991;42(4):729-33.
1990: Toru Maruyama; Masaki Otagiri; A Takadate
Characterization of drug binding sites on alpha 1-acid glycoprotein.
Chemical & pharmaceutical bulletin 1990;38(6):1688-91.
1989: Masaki Otagiri; R Yamamichi; Toru Maruyama; T Imai; A Suenaga; Yorishige Imamura; K Kimachi
Drug binding to alpha 1-acid glycoprotein studied by circular dichroism.
Pharmaceutical research 1989;6(2):156-9.
1987: Masaki Otagiri; Toru Maruyama; T Imai; Yorishige Imamura
Fluorescent investigations of binding of phenprocoumon to alpha 1-acid glycoprotein.
Journal of pharmaceutical sciences 1987;76(8):646-9.